Discovering chemical tools for acute myelogenous leukemia

发现治疗急性髓性白血病的化学工具

• 批准号: 8248294
• 负责人: Jing-Ruey Joanna Yeh
• 金额: $ 35.63万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-01 至 2015-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8248294
• 关键词: AML1-ETO fusion protein; Acute Myelocytic Leukemia; Address; Binding; Biological; Biological Models; Blast Cell; Blood; Cell Differentiation process; Cell Maturation; Cells; Chemical Modifier; Chemicals; Chimeric Proteins; Chromosomal translocation; Clinical; Complex; Core-Binding Factor; Defect; Development; Dicumarol; Disease; Disease model; Down-Regulation; Embryo; Enhancers; Erythroid Cells; Erythropoiesis; Genes; Granulopoiesis; Hematopoietic; Hematopoietic stem cells; Histone Deacetylase Inhibitor; Human; In Vitro; Lead; Mediating; Modeling; Molecular Abnormality; Mutate; Mutation; Oncogenes; Oncogenic; PTGS2 gene; Pathway interactions; Patients; Phenotype; Play; Research; Role; Screening procedure; Signal Pathway; Techniques; Testing; Therapeutic; Transgenic Organisms; Up-Regulation; Validation; Zebrafish; base; chemical genetics; chemotherapy; design; disease phenotype; drug candidate; expectation; follow-up; functional restoration; fusion gene; granulocyte; in vivo; killings; leukemia; leukemic stem cell; leukemogenesis; mouse model; new therapeutic target; novel therapeutics; promoter; public health relevance; research study; small molecule; stem cell differentiation; therapeutic target; therapy development; tool

DESCRIPTION (provided by applicant): Many leukemias, including acute myelogenous leukemia (AML), are caused by oncogenic mutations that (1) alter differentiation and (2) promote proliferation of multipotent hematopoietic progenitor cells. Most chemotherapies target proliferation of the bulk leukemia cells, but few target the differentiation defects of multipotent leukemia stem cells. Development of therapies that target leukemia stem cell differentiation has been hindered by the difficulties of modeling oncogene-disrupted cell fate decisions in vitro and the difficulties of conducting high-throughput small molecule screens in vivo. A system that models the effects of oncogenes on cell differentiation in vivo while also enabling high-throughput chemical screening could open the door to therapies that target leukemia stem cell differentiation. The oncogene AML1-ETO (AE) causes a differentiation defect in hematopoietic progenitor cells that leads to accumulation of granulocytic blast cells in AML patients. Expression of AE in developing zebrafish also disrupts hematopoietic progenitor cell differentiation, leading to accumulation of granulocytic blast cells resembling those from human AML patients. A pilot screen of 2100 small molecules conducted with AE- expressing zebrafish has identified three compound classes that block the effects of AE on hematopoietic progenitor cell differentiation. A larger small molecule screen is now proposed, with the expectation that it will discover additional compounds that antagonize AE function. Compounds discovered will be subjected to mechanistic studies and evaluated for therapeutic potential using human cells and mouse models of AML. The following specific aims are proposed: Aim 1. Screening for additional AE antagonists. Aim 2. Elucidating the mechanisms by which the AE antagonists suppress AE function. Aim 3. Validating the therapeutic utility of the AE antagonists. By exploiting the unique capabilities of the zebrafish for disease modeling and small molecule screening, the proposed project will provide powerful tools for dissecting the oncogenic pathways leading to AML and may point to promising new chemotherapeutic approaches for treating the disease. PUBLIC HEALTH RELEVANCE: Most chemotherapies for leukemia are designed to kill rapidly dividing cells, but they do not address the defects in cellular maturation that are a major contributor to the development of leukemia. This project will test thousands of potential drug candidates to discover those that can reverse the cell maturation defects in cells containing a common leukemia-causing gene. The primary objective of these studies is discovery and validation of new therapeutic techniques for treating leukemia.

描述（由申请人提供）：许多白血病，包括急性髓性白血病（AML），是由致癌突变引起的，这些突变（1）改变分化和（2）促进多能造血祖细胞增殖。大多数化学疗法靶向大量白血病细胞的增殖，但很少靶向多能白血病干细胞的分化缺陷。靶向白血病干细胞分化的疗法的开发受到体外建模癌基因破坏的细胞命运决定的困难和体内进行高通量小分子筛选的困难的阻碍。一个模拟癌基因对体内细胞分化影响的系统，同时还能够进行高通量化学筛选，这可能为靶向白血病干细胞分化的治疗打开大门。癌基因AML 1-ETO（AE）导致造血祖细胞的分化缺陷，导致AML患者中粒细胞母细胞的积累。AE在发育中的斑马鱼中的表达也破坏造血祖细胞分化，导致类似于来自人类AML患者的粒细胞母细胞的积累。用表达AE的斑马鱼进行的2100种小分子的中试筛选已经鉴定了阻断AE对造血祖细胞分化的作用的三种化合物类别。现在提出了一个更大的小分子筛选，期望它将发现拮抗AE功能的其他化合物。发现的化合物将进行机制研究，并使用人类细胞和小鼠AML模型评估治疗潜力。提出了以下具体目标：目标1。筛选其他AE拮抗剂。目标二。阐明AE拮抗剂抑制AE功能的机制。目标3.验证AE拮抗剂的治疗效用。通过利用斑马鱼在疾病建模和小分子筛选方面的独特能力，该项目将为解剖导致AML的致癌途径提供强大的工具，并可能为治疗该疾病提供有前途的新化疗方法。 公共卫生相关性：大多数白血病化疗的目的是杀死快速分裂的细胞，但它们没有解决细胞成熟的缺陷，这是白血病发展的主要原因。该项目将测试数千种潜在的候选药物，以发现那些可以逆转含有常见白血病致病基因的细胞中细胞成熟缺陷的药物。这些研究的主要目的是发现和验证治疗白血病的新治疗技术。